复宏汉霖(02696)_个股概要_股票价格_最新资讯_行情走势_历史数据 - 老虎社区

应交易所要求，美/港股行情延时15分钟展示，下载APP即可免费查看实时行情。

关闭

02696 复宏汉霖

休市中 09-04 16:08:03

70.100

+1.050

+1.52%

最高71.050	最低68.300	成交量88.16万
今开69.950	昨收69.050	日振幅3.98%
总市值382.05亿	流通市值243.95亿	总股本5.45亿
成交额6,183万	换手率0.25%	流通股本3.48亿
市净率--	ROE--	每股收益0.00
52周最高--	52周最低--	市盈率--
股息--	股息收益率--	ROA--

数据加载中...

北京优虎网络科技有限公司

免责声明:香港交易所资讯服务有限公司、其控股公司及／或该等控股公司的任何附属公司均竭力确保所提供信息的准确和可靠度，但不能保证其绝对准确和可靠，且亦不会承担因任何不准确或遗漏而引起的任何损失或损害的责任（不管是否侵权法下的责任或合约责任又或其它责任）

{"stockData":{"symbol":"02696","market":"HK","secType":"STK","nameCN":"复宏汉霖","latestPrice":70.1,"timestamp":1788509283006,"preClose":69.05,"halted":0,"volume":881557,"delay":0,"changeRate":0.015206372194062233,"floatShares":348000000,"shares":545000000,"eps":1.7643752843467013,"marketStatus":"休市中","change":1.05,"latestTime":"09-04 16:08:03","open":69.95,"high":71.05,"low":68.3,"amount":61825140,"amplitude":0.039826,"askPrice":70.2,"askSize":8800,"bidPrice":70.1,"bidSize":6300,"shortable":3,"etf":0,"ttmEps":1.8460234185032738,"tradingStatus":0,"nextMarketStatus":{"tag":"开盘","tradingStatus":2,"beginTime":1788744600000},"marketStatusCode":7,"adr":0,"listingDate":1569340800000,"exchange":"SEHK","adjPreClose":69.05,"openAndCloseTimeList":[[1788485400000,1788494400000],[1788498000000,1788508800000]],"volumeRatio":1.0754325362381418,"lotSize":100,"spreadScale":0,"tradeCurrency":"HKD"},"requestUrl":"/m/hq/s/02696","defaultTab":"news","newsList":[{"id":"2665363260","title":"对话复宏汉霖朱俊：AI不只是效率工具，还将成为重塑新药研发的决定性力量","url":"https://stock-news.laohu8.com/highlight/detail?id=2665363260","media":"新浪科技","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2665363260?lang=zh_cn&edition=full","pubTime":"2026-09-05 22:55","pubTimestamp":1788620100,"startTime":"0","endTime":"0","summary":"在AI对新药研发的影响方面，朱俊认为，AI不止能缩短研发周期，还能够成为新药研发的决定性力量。在竞争格局层面，朱俊认为AI将改变中国药企“靠体量获胜”的盈利模式。此外，朱俊还分享了AI在实际管线中的应用。公司一款减肥针剂资产，对标产品“能增肌减肥但亲和力低、要求剂量高，导致痤疮、肌痉挛等副作用”，而复宏汉霖通过AI找到相应表位，使亲和力提升20倍以上，副作用大幅减少。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.sina.com.cn/roll/2026-09-05/doc-iniquyin4906948.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"sina","symbols":["HK0000306685.HKD","HK0000320264.USD","HK0000320223.HKD","VTHR","HK0000306701.USD","ARTY","HK0000165453.HKD","QTOC","CHAT","AGIX","02696","AIPO","BK1161"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2665936888","title":"复宏汉霖朱俊：未来所有制药企业都是AI制药企业，不存在不依赖AI的生物制药企业","url":"https://stock-news.laohu8.com/highlight/detail?id=2665936888","media":"睿见Economy","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2665936888?lang=zh_cn&edition=full","pubTime":"2026-09-05 14:04","pubTimestamp":1788588240,"startTime":"0","endTime":"0","summary":"朱俊坦言，尽管近年来国家批准的创新药数量已领先全球，但临床疗效的提升依然艰难。他强调，如果AI不能进一步赋能，生物医药产业将继续处于原始状态。未来，所有的制药企业都必须是AI制药企业，不存在不依赖AI的生物制药企业。朱俊总认为，在全球变局下，只要企业能够用好AI、抓住精准人群并解决真实的临床痛点，即使十个机会中只能抓住一个，也足以支撑企业的长远发展。","market":"other","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.sina.com.cn/hy/hyjz/2026-09-05/doc-iniquccs3668085.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"sina","symbols":["01477","HK0000320223.HKD","AIPO","03069","ARTY","HK0000306685.HKD","HK0000320264.USD","MRNX","BK1161","BBP","QTOC","02696","IBBQ","HK0000306701.USD","HK0000165453.HKD","MRNY","CHAT","BK1574","AGIX","BK1191","VTHR"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1158076719","title":"复宏汉霖更新2026年8月股份变动月报表，注册股本增至5.45亿股","url":"https://stock-news.laohu8.com/highlight/detail?id=1158076719","media":"公告速递","labels":["SGX"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1158076719?lang=zh_cn&edition=full","pubTime":"2026-09-02 17:43","pubTimestamp":1788342192,"startTime":"0","endTime":"0","summary":"上海复宏汉霖生物技术股份有限公司于2026年9月2日披露2026年8月股份变动月报。报告期为2026年8月1日至8月31日，注册股本由原先的人民币34.78亿股和对应金额，增加5.28万股至人民币5.45亿股。同期失效购股权5.44万股，失效受限制股份单位5.44万份。截至报告期末，普通股H股总数约为3.48亿股，其他类别非上市股份保持1.97亿股不变。本月内公司未发生股份回购、注销或库藏股相关活动。本月报由董事Wenjie ZHANG签署并提交。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02696"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2664183797","title":"摩根士丹利在复宏汉霖的H股好仓比例上升0.61%至5.09%","url":"https://stock-news.laohu8.com/highlight/detail?id=2664183797","media":"南方财经网","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2664183797?lang=zh_cn&edition=full","pubTime":"2026-09-01 17:21","pubTimestamp":1788254460,"startTime":"0","endTime":"0","summary":"南财智讯9月1日电，香港交易所披露信息显示，MorganStanley（摩根士丹利）在复宏汉霖的H股好仓（L）比例于8月26日从4.48%上升至5.09%。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"stock_eastmoney","url":"http://finance.eastmoney.com/a/202609013861553328.html","rn_cache_url":null,"directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202609013861553328.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["HK0000306701.USD","02696","HK0000165453.HKD","HK0000306685.HKD","BK1161","HK0000320223.HKD","HK0000320264.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2662721062","title":"港股异动 | 复宏汉霖(02696)早盘涨近7% 上半年海外产品收入增长159% 花旗上调业绩预测及目标价","url":"https://stock-news.laohu8.com/highlight/detail?id=2662721062","media":"智通财经","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2662721062?lang=zh_cn&edition=full","pubTime":"2026-08-27 10:17","pubTimestamp":1787797076,"startTime":"0","endTime":"0","summary":"智通财经APP获悉，复宏汉霖早盘涨近7%，截至发稿，涨5.86%，报72.3港元，成交额1416.55万港元。消息面上，复宏汉霖发布中期业绩，上半年收入为35.9亿元人民币，同比增长27%；净利4.3亿元，同比增长10%。该行调整对其今明两年收入预测8%及3%，每股纯利预测上调至分别1.52元及1.79元人民币，将目标价由95港元轻微上调至95.2港元。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1486732.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["VXUS","02696","KCAI"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2662711923","title":"GIC Private Limited增持复宏汉霖(02696)23.22万股 每股作价约68.67港元","url":"https://stock-news.laohu8.com/highlight/detail?id=2662711923","media":"智通财经网","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2662711923?lang=zh_cn&edition=full","pubTime":"2026-08-26 19:55","pubTimestamp":1787745327,"startTime":"0","endTime":"0","summary":"8月21日，GIC Private Limited增持复宏汉霖(02696)23.22万股，每股作价68.6666港元，总金额约为1594.44万港元。","market":"us","thumbnail":"https://img.zhitongcaijing.com/image/20260826/20260826195606_76195.png?x-oss-process=image/format,jpg/quality,Q_80/resize,w_250","type":0,"news_type":0,"thumbnails":["https://img.zhitongcaijing.com/image/20260826/20260826195606_76195.png?x-oss-process=image/format,jpg/quality,Q_80/resize,w_250"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1486296.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"highlight_zhitongcaijin","symbols":["BK1161","HK0000306685.HKD","GIC","HK0000320264.USD","EWH","02696","BK4104","HK0000320223.HKD","HK0000306701.USD","HK0000165453.HKD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1116954231","title":"复宏汉霖：GIC Private Limited增持，好仓比例升至5.03%","url":"https://stock-news.laohu8.com/highlight/detail?id=1116954231","media":"港股披露","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1116954231?lang=zh_cn&edition=full","pubTime":"2026-08-26 17:12","pubTimestamp":1787735522,"startTime":"0","endTime":"0","summary":"GIC Private Limited于2026年8月21日以每股均价68.6666港元买入复宏汉霖股份23.22万股，涉资约1594.44万港元。GIC Private Limited此次增持前持有复宏汉霖好仓1725.95万股，占比4.96%；增持后持股量为1749.17万股，好仓比例升至5.03%。原文链接：Hong Kong Exchanges and Clearing Limited","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02696"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2662793807","title":"花旗：微升复宏汉霖(02696)目标价至95.2港元 重申“买入”评级 上半年自然增长稳固","url":"https://stock-news.laohu8.com/highlight/detail?id=2662793807","media":"智通财经","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2662793807?lang=zh_cn&edition=full","pubTime":"2026-08-26 15:07","pubTimestamp":1787728029,"startTime":"0","endTime":"0","summary":"智通财经APP获悉，花旗发布研报称，复宏汉霖(02696)2026年上半年自然增长稳固，收入为35.9亿元人民币，同比增长27%，净利4.3亿元，同比增长10%。研发开支因研发进度加快而同比上升41%至8.26亿元。管理层对中长期前景持乐观态度，预期serplulimab高峰销售额达100亿元，并于未来数年全球推出10款以上产品。由于公司强大的内部创新能力，该行对其内生增长及业务拓展潜力感到乐观。该行调整对其今明两年收入预测8%及3%，每股纯利预测上调至分别1.52元及1.79元人民币，将目标价由95港元轻微上调至95.2港元。维持“买入”评级。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1485888.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["EWH","02696"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2662764623","title":"大行评级丨花旗：微升复宏汉霖目标价至95.2港元，维持“买入”评级","url":"https://stock-news.laohu8.com/highlight/detail?id=2662764623","media":"格隆汇","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2662764623?lang=zh_cn&edition=full","pubTime":"2026-08-26 11:55","pubTimestamp":1787716503,"startTime":"0","endTime":"0","summary":null,"market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.gelonghui.com/rss/live/live.xml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_gelonghui","symbols":["HK0000306701.USD","02696","HK0000165453.HKD","HK0000306685.HKD","BK1161","HK0000320223.HKD","HK0000320264.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2662273532","title":"复宏汉霖(02696.HK)向受托人配发23475股新股","url":"https://stock-news.laohu8.com/highlight/detail?id=2662273532","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2662273532?lang=zh_cn&edition=full","pubTime":"2026-08-25 18:26","pubTimestamp":1787653598,"startTime":"0","endTime":"0","summary":null,"market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.zhitongcaijing.com/immediately.html?type=ganggu","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_zhitongcaijing","symbols":["HK0000306701.USD","02696","BK1161","HK0000320223.HKD","HK0000306685.HKD","HK0000320264.USD","HK0000165453.HKD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1156407690","title":"复宏汉霖：8月25日已发行股本变动，合计新增26,600股","url":"https://stock-news.laohu8.com/highlight/detail?id=1156407690","media":"公告速递","labels":["SGX"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1156407690?lang=zh_cn&edition=full","pubTime":"2026-08-25 18:25","pubTimestamp":1787653554,"startTime":"0","endTime":"0","summary":"2026年8月25日，上海复宏汉霖生物技术股份有限公司公布翌日披露报表，披露其已发行股份出现变动。根据公告，本次新增股份主要来源于依据公司于2025年7月21日采纳的2025年H股购股权计划下购股权行使，以及2025年H股受限制股份单位计划所配发及发行的股份。本次合计新增26,600股，约占变动前已发行股本的0.01%。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":"复宏汉霖：8月25日已发行股本变动，合计新增26,600股","news_tag":"SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02696"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2662078846","title":"港股通配置窗口临近，营收35.88亿净利4.30亿，复宏汉霖(02696)中报夯实增长持续性","url":"https://stock-news.laohu8.com/highlight/detail?id=2662078846","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2662078846?lang=zh_cn&edition=full","pubTime":"2026-08-25 11:10","pubTimestamp":1787627451,"startTime":"0","endTime":"0","summary":"8月21日，复宏汉霖2026年中期业绩正式出炉。此次复宏汉霖的中报显示出其高质量稳健增长的营收与利润表现：报告期内，公司实现营收35.882亿元，同比增长27.3%;净利润实现4.304亿元，同比增长10.3%。今年上半年，复宏汉霖盈利增长贡献主要来自国内、海外两大市场协同深耕。而在乳腺癌治疗领域，复宏汉霖于报告期内实现该领域产品全球销售收入16.98亿元。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1484842.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["FLHK","02696"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2661476702","title":"复宏汉霖上半年营收净利双增，获纳入恒生综合指数成份股","url":"https://stock-news.laohu8.com/highlight/detail?id=2661476702","media":"新浪财经","labels":["corporation"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2661476702?lang=zh_cn&edition=full","pubTime":"2026-08-24 10:52","pubTimestamp":1787539920,"startTime":"0","endTime":"0","summary":"8月24日消息，复宏汉霖近日发布2026年度中期业绩。此外，复宏汉霖还宣布，根据恒生指数有限公司于2026年8月21日公布的截至2026年6月30日之恒生指数系列季度检讨结果，公司获选并将被纳入恒生综合指数成份股，自2026年9月7日起正式生效。复宏汉霖执行董事、首席执行官朱俊表示，2026年是复宏汉霖向C-MNC迈进的关键加速之年。朱俊谈到，未来公司将始终锚定患者未被满足的临床需求，全面深化公司全球化2.0战略布局。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.sina.com.cn/roll/2026-08-24/doc-inipkriy6243986.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"sina","symbols":["02696","HSCI"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2661506211","title":"每周股票复盘：复星医药（600196）复宏汉霖与Sandoz签许可协议","url":"https://stock-news.laohu8.com/highlight/detail?id=2661506211","media":"证券之星","labels":["corporation"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2661506211?lang=zh_cn&edition=full","pubTime":"2026-08-23 01:24","pubTimestamp":1787419452,"startTime":"0","endTime":"0","summary":"截至2026年8月21日收盘，复星医药报收于23.56元，较上周的24.21元下跌2.68%。本周关注点公司公告汇总：复宏汉霖与Sandoz AG签订合作框架协议，就至多10款生物类似药开展海外合作。公司公告汇总2026年8月16日，复星医药控股子公司复宏汉霖与Sandoz AG签订《合作框架协议》，就至多10款单克隆抗体或抗体偶联药物生物类似药开展海外注册、商业化、开发、生产等许可合作。复宏汉霖可收取首付款、里程碑款等合计至多31,400万美元。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026082300000136.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK1515","BK0183","BK0187","02196","BK1593","BK0012","HK0000165453.HKD","BK0175","BK0188","BK0028","BK1161","600196","02696","BK0060","BK0096","BK1191","BK0239","HK0000306685.HKD","HK0000306701.USD","HK0000320223.HKD","BK0196","HK0000320264.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2661156662","title":"复宏汉霖上半年营收35.9亿元 全球商业化能力持续释放","url":"https://stock-news.laohu8.com/highlight/detail?id=2661156662","media":"证券日报","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2661156662?lang=zh_cn&edition=full","pubTime":"2026-08-22 10:39","pubTimestamp":1787366340,"startTime":"0","endTime":"0","summary":"8月21日，上海复宏汉霖生物技术股份有限公司（以下简称“复宏汉霖”）发布2026年中期业绩报告。报告期内，公司全球商业化能力持续提升，核心产品放量推动业绩增长，创新管线加速推进。数据显示，2026年上半年，复宏汉霖实现营业收入35.88亿元，同比增长27.3%；实现净利润4.30亿元，同比增长10.3%。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"stock_eastmoney","url":"http://finance.eastmoney.com/a/202608223850132388.html","rn_cache_url":null,"directOrigin":true},"property":["earning"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202608223850132388.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["02696"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2661296081","title":"复宏汉霖上半年净利润同比增长10.3%","url":"https://stock-news.laohu8.com/highlight/detail?id=2661296081","media":"南方财经网","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2661296081?lang=zh_cn&edition=full","pubTime":"2026-08-21 22:32","pubTimestamp":1787322720,"startTime":"0","endTime":"0","summary":"南方财经8月21日电，复宏汉霖（2696.HK）发布2026年度中期业绩。报告期内，公司展现出强劲的内生增长动能与高质量造血能力，实现营收人民币35.882亿元，同比增长27.3%；净利润4.304亿元，同比增长10.3%。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"stock_eastmoney","url":"http://finance.eastmoney.com/a/202608213849710716.html","rn_cache_url":null,"directOrigin":true},"property":["earning"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202608213849710716.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["02696"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1160126283","title":"新闻稿：复宏汉霖发布2026年中期业绩——盈利持续跃升，全球价值兑现加速，迈向C-MNC步伐加快","url":"https://stock-news.laohu8.com/highlight/detail?id=1160126283","media":"投资观察","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1160126283?lang=zh_cn&edition=full","pubTime":"2026-08-21 21:03","pubTimestamp":1787317411,"startTime":"0","endTime":"0","summary":"上海，2026年8月21日 /PRNewswire/ -- 8月21日，复宏汉霖公布其2026财年中期业绩。2026年上半年，复宏汉霖实现非国际财务报告准则利润人民币5.723亿元，同比大幅增长46.7%；调整后息税折旧摊销前利润为人民币9.041亿元，同比增长35.2%。关键财务及运营指标保持稳健上行态势。得益于核心产品在全球市场的持续放量，以及全价值链端到端的精益运营，公司的收入规模与盈利质量正同步增强。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["HK0000165453.HKD","BK4585","BK4233","LU2065732104.USD","BK4588","BK4604","TM","BK4528","UK","HK0000320264.USD","BK4097","BK1161","BK4099","HK0000320223.HKD","BK4232","HK0000306685.HKD","03160","BK4022","HK0000306701.USD","R","02696","BK4205","BK4555","PRGS"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1145119239","title":"复宏汉霖2026年中期业绩：盈利持续跃升，全球价值验证推进，C-Mnc目标加速实现","url":"https://stock-news.laohu8.com/highlight/detail?id=1145119239","media":"美股速递","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1145119239?lang=zh_cn&edition=full","pubTime":"2026-08-21 21:00","pubTimestamp":1787317213,"startTime":"0","endTime":"0","summary":"复宏汉霖公布2026年中期业绩报告，展现出令人瞩目的盈利持续跃升势头，同时在全球价值验证方面取得显著进展，正加速迈向C-Mnc的战略目标。\n公司经营表现强劲，盈利能力稳步增强，这一积极态势充分反映了其战略执行的有效性与市场竞争力。在全球范围内，复宏汉霖的价值主张正不断获得验证——无论是产品管线的临床推进，还是商业化布局的拓展，都呈现出系统性的良好发展格局。\n值得关注的是，复宏汉霖在实现C-Mnc这一关键里程碑的道路上步伐明显加快。这一进展不仅彰显了公司在生物制药领域的持续创新能力，也为其长期可持续发展奠定了坚实基础。随着全球业务版图的进一步扩大，公司有望在多个核心市场释放更大的价值潜力。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["HK0000320264.USD","HK0000320223.HKD","BK1161","HK0000165453.HKD","02696","HK0000306685.HKD","HK0000306701.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2661293697","title":"复宏汉霖：上半年总收入同比增27.3%至35.88亿元","url":"https://stock-news.laohu8.com/highlight/detail?id=2661293697","media":"财中社","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2661293697?lang=zh_cn&edition=full","pubTime":"2026-08-21 20:56","pubTimestamp":1787316960,"startTime":"0","endTime":"0","summary":"8月21日，复宏汉霖（02696）发布截至2026年6月30日止六个月的中期业绩公告。公告显示，公司总收入约为35.88亿元，较去年同期的28.2亿元增加约7.69亿元，增幅约27.3%。收入主要来源于药物销售及研究与开发服务。研发支出方面，公司确认研发开支约为14.51亿元，较去年同期的9.95亿元增加约4.55亿元，主要用于加大对创新型研发项目的投入。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"stock_eastmoney","url":"http://finance.eastmoney.com/a/202608213849579774.html","rn_cache_url":null,"directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202608213849579774.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["HK0000306701.USD","02696","HK0000165453.HKD","HK0000306685.HKD","BK1161","HK0000320223.HKD","HK0000320264.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2661629866","title":"复宏汉霖(02696.HK)上半年营收35.882亿元 海外产品销售收入同比增长159.4%","url":"https://stock-news.laohu8.com/highlight/detail?id=2661629866","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2661629866?lang=zh_cn&edition=full","pubTime":"2026-08-21 20:31","pubTimestamp":1787315492,"startTime":"0","endTime":"0","summary":null,"market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.zhitongcaijing.com/immediately.html?type=ganggu","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_zhitongcaijing","symbols":["BK1161","HK0000320223.HKD","HK0000165453.HKD","HK0000306685.HKD","HK0000306701.USD","02696","HK0000320264.USD"],"isVideo":false,"video":null,"gpt_icon":0}],"profile":{"stockEarnings":[{"period":"1week","weight":-0.0007},{"period":"1month","weight":0.1162},{"period":"3month","weight":0.1645},{"period":"6month","weight":0.0159},{"period":"1year","weight":-0.0728},{"period":"ytd","weight":0.2287}],"compareEarnings":[{"period":"1week","weight":0.0026},{"period":"1month","weight":-0.0102},{"period":"3month","weight":0.0276},{"period":"6month","weight":-0.0041},{"period":"1year","weight":0.0236},{"period":"ytd","weight":0.0008}],"compareStock":{"symbol":"HSI","name":"恒生指数"},"description":"上海复宏汉霖生物技术股份有限公司是一家主要从事生物制药研发、生物制药服务及生物制药生产与销售的中国公司。该公司的主要产品包括汉曲优（注射用曲妥珠单抗）、汉奈佳（马来酸奈拉替尼片）、汉斯状（斯鲁利单抗注射液）、汉利康（利妥昔单抗注射液）、汉达远（阿达木单抗注射液）、汉贝泰（贝伐珠单抗注射液）等。该公司的产品主要应用于乳腺癌辅助治疗、转移性乳腺癌及转移性胃癌治疗、转移性非鳞状非小细胞肺癌、多关节型幼年特发性关节炎治疗等。该公司主要在中国国内和海外市场开展业务。","yearOnYearQuotes":[{"month":1,"riseRate":0.428571,"avgChangeRate":-0.044394},{"month":2,"riseRate":0.714286,"avgChangeRate":0.117695},{"month":3,"riseRate":0.571429,"avgChangeRate":-0.008815},{"month":4,"riseRate":0.857143,"avgChangeRate":0.12138},{"month":5,"riseRate":0.428571,"avgChangeRate":-0.033714},{"month":6,"riseRate":0.571429,"avgChangeRate":0.085211},{"month":7,"riseRate":0.428571,"avgChangeRate":0.040127},{"month":8,"riseRate":0.571429,"avgChangeRate":0.005816},{"month":9,"riseRate":0.142857,"avgChangeRate":-0.100355},{"month":10,"riseRate":0.285714,"avgChangeRate":-0.025526},{"month":11,"riseRate":0.571429,"avgChangeRate":0.058675},{"month":12,"riseRate":0.714286,"avgChangeRate":-0.023816}],"exchange":"SEHK","name":"复宏汉霖","nameEN":"HENLIUS"},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"isLaohu8Offline":false,"tenantId":"TBCN","deviceId":"web-server-community-laohu8-v3","version":"4.44.1","shortVersion":"4.44.1","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"复宏汉霖(02696)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供复宏汉霖(02696)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"复宏汉霖,02696,复宏汉霖股票,复宏汉霖股票老虎,复宏汉霖股票老虎国际,复宏汉霖行情,复宏汉霖股票行情,复宏汉霖股价,复宏汉霖股市,复宏汉霖股票价格,复宏汉霖股票交易,复宏汉霖股票购买,复宏汉霖股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"复宏汉霖(02696)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供复宏汉霖(02696)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}